About Biocon Our Business Research & Development Biocon's Technology Investors Media Careers CSR
  Press Releases
  Media Stories
  Download Center
  Video Gallery
  Photo Gallery
  Media Contacts

Media Stories

2019 2018 2017 2016 2015

August 2020
07 August Webinar on "Compassionate Capitalism" with Kiran Mazumdar-Shaw
July 2020
25 July Biocon Bets Big on Biosimilars, Generics Unit for Fast Growth
25 July Itolizumab to be a great opportunity for Biocon
14 July Initial response to Covid drug Itolizumab 'extremely encouraging', says Biocon
14 July Biocon eyes global markets to supply drug
14 July Itolizumab best used pre-ventilator: Data
14 July Mint Lite
June 2020
16 June Biosimilar Drugs can Help us Reach $1b Target Soon
06 June Kiran Mazumdar-Shaw named EY World Entrepreneur of 2020
May 2020
19 May Covid provides larger opportunity to shape the biosimilar landscape
16 May Will invest Rs2,000 crore in small molecules in 3-4 years
March 2020
12 Mar Biocon wins patent case against Sanofi
10 Mar Biocon's cancer biosimilar gets US FDA acceptance for review
February 2020
22 Feb Biocon chief is EY entrepreneur for 2019
January 2020
27 Jan Biocon Biologics Eyes $200M. Plans IPO in 2 Yrs: Mazumdar-Shaw
24 Jan Biocon Q3 PBT up 9%
08 Jan Biocon optimistic about hitting $1 billion in revenue by FY22 on back of new launches





Recommended sites Biocon on  
About Us

Investor Relations
Media Relations
Site Map
Contact Us
Our Growth Accelerators
Fact Sheet
Branded Formulations
Research Services
Active Discovery Program

Karnataka Vision Group on BT
Syngene International
Biocon Academy

    Linked In   
  Report adverse event/side effects and product complaints    
  * Disclaimer            © 2018, Biocon. All Rights Reserved